Multiple regression analysis of outcomes after nonmyeloablative umbilical cord blood transplantation
| Outcome . | Odds ratio, relative risk (95% CI) . | P . |
|---|---|---|
| Graft failure | ||
| HLA match 4/6* | 5.0 (0.6-41.5) | .14 |
| Double UCB donor† | 2.4 (0.3-20.8) | .42 |
| TNC dose‡ | ||
| 2.9 to 3.6 × 107/kg | 1.5 (0.2-9.8) | .62 |
| 3.7 to 4.3 × 107/kg | 3.2 (0.6-18.2) | .18 |
| No less than 4.4 × 107/kg | 2.6 (0.4-16.3) | .31 |
| Grades II-IV acute GVHD | ||
| Double UCB donor† | 2.3 (1.0-5.1) | .04 |
| No ATG in the preparative regimen§ | 2.2 (1.2-4.0) | <.01 |
| Transplantation-related mortality‖: | ||
| Pretransplantation high-risk clinical features¶ | 3.9 (1.6-9.1) | <.01 |
| Event-free survival | ||
| Double UCB donor† | 0.6 (0.3-1.0) | .07 |
| Pretransplantation high-risk clinical features¶ | 2.2 (1.3-3.8) | <.01 |
| Overall survival# | ||
| Pretransplantation high-risk clinical features¶ | 3.0 (1.7-5.2) | <.01 |
| Grades III and IV acute GVHD** | 1.9 (1.0-3.5) | .04 |
| Outcome . | Odds ratio, relative risk (95% CI) . | P . |
|---|---|---|
| Graft failure | ||
| HLA match 4/6* | 5.0 (0.6-41.5) | .14 |
| Double UCB donor† | 2.4 (0.3-20.8) | .42 |
| TNC dose‡ | ||
| 2.9 to 3.6 × 107/kg | 1.5 (0.2-9.8) | .62 |
| 3.7 to 4.3 × 107/kg | 3.2 (0.6-18.2) | .18 |
| No less than 4.4 × 107/kg | 2.6 (0.4-16.3) | .31 |
| Grades II-IV acute GVHD | ||
| Double UCB donor† | 2.3 (1.0-5.1) | .04 |
| No ATG in the preparative regimen§ | 2.2 (1.2-4.0) | <.01 |
| Transplantation-related mortality‖: | ||
| Pretransplantation high-risk clinical features¶ | 3.9 (1.6-9.1) | <.01 |
| Event-free survival | ||
| Double UCB donor† | 0.6 (0.3-1.0) | .07 |
| Pretransplantation high-risk clinical features¶ | 2.2 (1.3-3.8) | <.01 |
| Overall survival# | ||
| Pretransplantation high-risk clinical features¶ | 3.0 (1.7-5.2) | <.01 |
| Grades III and IV acute GVHD** | 1.9 (1.0-3.5) | .04 |
Odds ratios are in rows 1 through 7, relative risk in rows 8 to end.
HLA match 5-6/6 (baseline odds ratio of 1.0). For recipients of 2 UCB units we considered the HLA-matching of the worst matched unit.
Single UCB donor unit (baseline odds ratio or relative risk of 1.0).
TNC dose less than 2.9 × 107/kg (baseline odds ratio of 1.0).
Presence of ATG in the preparative regimen (baseline relative risk of 1.0).
Causes of transplant-related death at 6 months included GVHD,3 graft failure,1 EBV-induced lymphoma,1 multiple organ failure/infection,12 and hemorrhage.3
Absence of high-risk clinical features (baseline relative risk of 1.0).
Overall causes of death included disease relapse or progression,27 infection and organ failure,12 GVHD,6 hemorrhage,3 and EBV-induced posttransplant lymphoproliferative disease,2 multiple organ failure,2 and graft failure.1
Absence of grades III and IV acute GVHD (baseline relative risk of 1.0).